The rigorous testing to meet the standards required by the health ministries of France and other European countries demonstrate that Flavay® is highly bioavailable, nontoxic, nonallergenic, noncarcinogenic, nonmutagenic, will not cause birth defects, and is completely safe. (2,3,4,8,90-95)

Proven Safety of Flavay®

with More Than 60 Years of Human Use

After more than 60 years of human use, no adverse effects have been observed. Furthermore, intensive biological, toxicological, pharmacological and analytical research was conducted for the purpose of registration in France and other countries in Europe. In one study, daily doses of up to 35,000 mg for six months were determined to cause no adverse effects. Flavay® was also clinically tested, in particular for all sorts of symptoms related to venolymphatic insufficiencies. The spin-off is a goldmine of data: The rigorous testing to meet the standards required by the health ministries of France, Germany and other European countries demonstrate that Flavay® is highly bioavailable, nontoxic, nonallergenic, noncarcinogenic, nonmutagenic, will not cause birth defects, and is completely safe. (2,3,4,8,90-95)

Dr. Masquelier’s unequaled manufacturing process has been conducted for half a century at the very same facilities in France, and under the control of French Pharmaceutical inspection. These time-proven standards serve as a reliable assurance of the quality, consistency, bioavailability and safety of Flavay®.

Who can take Flavay®?

Licensed and sold for cardiovascular health in France for more than 60 years, the cardiovascular protective activity of Flavay® has been established by many significant studies. (1-4)

[Click here for MORE...]

Nearly everyone, from the very young to the elderly. Flavay® has no known contraindications (conditions under which it should not be used). Flavay® is completely safe and nontoxic. In fact, clinical trials have been conducted in which pregnant women (troubled by varicose veins and other circulatory problems in the legs) safely used Flavay®. (2,3,8)

Flavay® may enhance the anticoagulant effects of anticoagulant drugs (such as Coumadin or heparin). Notify your physician if you are taking anticoagulant drugs, as a blood test may indicate to your physician that the drug dose may be reduced if Flavay® or Flavay Plus® is being consumed. This is because Flavay® has been shown to normalize the reactivity ("stickiness") of blood platelets. (10,103,202) [Click here for MORE...]

Safety of Flavay Plus®

In addition to the information above about Flavay®: The essential vitamins and minerals in Flavay Plus® are naturally-derived and completely safe when used as directed on the label.

Flavay Plus® includes phosphatidyl serine, derived from soy lecithin, which has been proven safe in standard toxicology tests. From the large number of human studies conducted, phosphatidyl serine has developed a flawless safety record and proven compatible with a wide array of medications. (110,114-117,119,147)

  • SOURCES:

Flavay and Flavay Plus

Buy Now

Call for excellent service:

1-800-200-1203

We gladly accept the following
major credit cards:
Visa MasterCard Discover American Express

  • 1. Masquelier, J. Plant extract with a proanthocyanidins content as a therapeutic agent having radical scavenging effect and use thereof. U.S. Patent No. 4,698,360, 1987.
  • 2. Masquelier, J. A lifetime devoted to OPC and [pyc]. Alfa Omega Editrice, Pub., 1996.
  • 3. Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice, Publishers, 1995.
  • 4. Schwitters, B., Dr. Masquelier's mark on health. Alfa Omega Editrice, Publishers, 2004.
  • 6. Masquelier J., [pyc]s: recent advances in the therapeutical activity of procyanidins. Natural Products as Medicinal Agents, Vol. 1, Hippokrates Verlag, Stuttgart, pp. 243-256, 1981.
  • 8. Passwater, R.A., et al. super 'protector' nutrient. Keats Publishing, Inc., 1994. Keats Publishing, Inc., 1985.
  • 11. Lieberman, S., et al. The real vitamin & mineral book: going beyond the RDA. Avery Pub., 1990.
  • 103. Rohdewald, P. [pyc]. Vol 7 of Flavonoids in Health and Disease, edited by C. Rice-Evans and L. Packer. New York: Marcel Dekker Inc., 1998.
  • 114. Cenacchi T., et al. Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging, 5: 123–133, 1993.
  • 115. Maggioni M., Picotti GB, Bondiolotti GP et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand. 81: 265–270, 1990.
  • 116. Brambilla, F., Maggioni, M., Panerai, A.E., et al. Beta-endorphin concentration in peripheral blood mononuclear cells of elderly depressed patients—effects of phosphatidylserine therapy. Neuropsychobiology, 34: 18–21, 1996.
  • 117. Monteleone P., Maj M., Beinat L., Natale M., Kemali, D. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm, 43: 385–388, 1992.
  • 118. Heiss W.D., et al. Activation PET as an instrument to determine therapeutic efficacy in Alzheimer's disease. Ann N Y Acad Sci 1993 Sep 24;695:327-31.
  • 119. Funfgeld, E.W., Baggen, M., Nedwidek, P., Richstein, B., Mistlberger, G. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer’s type (SDAT). Prog Clin Biol Res, 317:1235-46, 1989.
  • [Click here for MORE...]